UPDATE: Citigroup Raises Eli Lilly PT to $60 on Eli Lilly on Potential Upside
Citigroup maintained Eli Lilly and Company (NYSE: LLY) with a Buy rating and raised the price target from $55.00 to $60.00.
Citigroup noted, "Lilly's base business is performing ahead of our expectations (Alimta, Elanco, Diabetes and Emerging markets). Consequently, we continue to see upside for Lilly due to the asymmetric risk reward given the minimal value being discounted for the key pipeline agent ramucirumab (cancer). Buy-rated Pfizer, Lilly and Forest remain our favoured names in US pharma."
Eli Lilly closed at $54.32 on Tuesday.
Latest Ratings for LLY
|Dec 2016||Morgan Stanley||Upgrades||Equal-Weight||Overweight|
|Nov 2016||Atlantic Equities||Downgrades||Overweight||Neutral|
|Nov 2016||BMO Capital||Downgrades||Outperform||Market Perform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.